5 Key Takeaways

• 1

  Companion diagnostics are essential for matching patients with effective targeted therapies, but their adoption in routine care is slow.

• 2

  The transition from research-grade to clinical-grade testing requires significant investment, regulatory approval, and time.

• 3

  Operational integration of assays into laboratory workflows is crucial for effective implementation of precision medicine.

• 4

  Reimbursement challenges, including the need for extensive clinical evidence, significantly hinder the adoption of precision diagnostics.

• 5

  Inequities in biomarker testing access between academic centers and community hospitals can negatively impact patient outcomes.